XSHG
688321
Market cap1.59bUSD
Oct 09, Last price
24.31CNY
1D
1.04%
1Q
-12.36%
IPO
-71.42%
Name
Shenzhen Chipscreen Biosciences Co Ltd
Chart & performance
P/E
210.82
P/S
11.87
EPS
0.12
Div yield, %
—
Shrs. gr., 5y
-0.11%
Rev. gr., 5y
27.49%
Revenues
908m
+37.93%
Net income
51m
P
CFO
97m
+27.37%
Dividend
May 14, 20260.058 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 2001 and headquartered in Shenzhen, China, Chipscreen Biosciences specializes in the discovery, development, and commercialization of innovative small-molecule pharmaceuticals. The company cultivates a pipeline of novel drug candidates and precursor compounds, all of which are progressing through diverse research phases and are protected by extensive global intellectual property rights. Its key therapeutic areas of focus encompass oncology, metabolic disorders, and autoimmune conditions.
Key people
Jianxun Li
Finance Director, General Manager, Director · since 2025
Xianping Lu
Chairman of the Board · since 2025
Zhibin Li
Deputy General Manager · since 2001
Desi Pan
Chief Scientific Officer, Deputy General Manager · since 2020
Liangji She
Deputy General Manager · since 2013
Libin Zhang
Deputy General Manager · since 2020
Ou Hai
Deputy General Manager, Secretary of the Board, Director · since 2018
Weihua Li
Director · since 2023
Hanpeng Yang
Director · since 2021
Min Huang
Independent Director · since 2024
Yonggen Luo
Independent Director · since 2024
Independent Director · since 2024
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||